Compare Crispr Therapeutics AG (CRSP) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Self-Driving EV and Tech — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while iShares Self-Driving EV and Tech trades at $33.34 (market cap $264.50M). The key difference: Crispr Therapeutics AG is far larger — about 18.4× iShares Self-Driving EV and Tech's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares Self-Driving EV and Tech for 73 Days on average.
| CRSP | IDRV | |
|---|---|---|
Market Cap | $4.88B | $264.50M |
Volume | 2,861,747 | 48,021 |
Sector | Health | Sector/Thematic |
52-Week High | $73.97 | $45.48 |
52-Week Low | $44.34 | $32.68 |
Typical Hold Time | 77 Days | 73 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
IDRV trades at $33.34, down slightly (-0.06%) with a bearish technical signal. Moving averages indicate selling pressure while oscillators remain neutral. The stock faces resistance at $34 and support at $33. Recent news highlights mixed EV market conditions with strong European demand but weaker US adoption following subsidy changes. Chinese competition and regulatory uncertainties create headwinds for the sector.
The outlook remains cautious given technical weakness and sector challenges. Investment opportunity exists in global EV growth trends, particularly in Europe and China. Key risks include US regulatory uncertainty, Chinese market access restrictions, and volatile oil prices affecting consumer EV adoption decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
